Is It Too Late? PAGE 58
Total Page：16
File Type：pdf, Size：1020Kb
Load more
Recommended publications
-
Arizona 500 2021 Final List of Songs
ARIZONA 500 2021 FINAL LIST OF SONGS # SONG ARTIST Run Time 1 SWEET EMOTION AEROSMITH 4:20 2 YOU SHOOK ME ALL NIGHT LONG AC/DC 3:28 3 BOHEMIAN RHAPSODY QUEEN 5:49 4 KASHMIR LED ZEPPELIN 8:23 5 I LOVE ROCK N' ROLL JOAN JETT AND THE BLACKHEARTS 2:52 6 HAVE YOU EVER SEEN THE RAIN? CREEDENCE CLEARWATER REVIVAL 2:34 7 THE HAPPIEST DAYS OF OUR LIVES/ANOTHER BRICK IN THE WALL PART TWO ANOTHER BRICK IN THE WALL PART TWO 5:35 8 WELCOME TO THE JUNGLE GUNS N' ROSES 4:23 9 ERUPTION/YOU REALLY GOT ME VAN HALEN 4:15 10 DREAMS FLEETWOOD MAC 4:10 11 CRAZY TRAIN OZZY OSBOURNE 4:42 12 MORE THAN A FEELING BOSTON 4:40 13 CARRY ON WAYWARD SON KANSAS 5:17 14 TAKE IT EASY EAGLES 3:25 15 PARANOID BLACK SABBATH 2:44 16 DON'T STOP BELIEVIN' JOURNEY 4:08 17 SWEET HOME ALABAMA LYNYRD SKYNYRD 4:38 18 STAIRWAY TO HEAVEN LED ZEPPELIN 7:58 19 ROCK YOU LIKE A HURRICANE SCORPIONS 4:09 20 WE WILL ROCK YOU/WE ARE THE CHAMPIONS QUEEN 4:58 21 IN THE AIR TONIGHT PHIL COLLINS 5:21 22 LIVE AND LET DIE PAUL MCCARTNEY AND WINGS 2:58 23 HIGHWAY TO HELL AC/DC 3:26 24 DREAM ON AEROSMITH 4:21 25 EDGE OF SEVENTEEN STEVIE NICKS 5:16 26 BLACK DOG LED ZEPPELIN 4:49 27 THE JOKER STEVE MILLER BAND 4:22 28 WHITE WEDDING BILLY IDOL 4:03 29 SYMPATHY FOR THE DEVIL ROLLING STONES 6:21 30 WALK THIS WAY AEROSMITH 3:34 31 HEARTBREAKER PAT BENATAR 3:25 32 COME TOGETHER BEATLES 4:06 33 BAD COMPANY BAD COMPANY 4:32 34 SWEET CHILD O' MINE GUNS N' ROSES 5:50 35 I WANT YOU TO WANT ME CHEAP TRICK 3:33 36 BARRACUDA HEART 4:20 37 COMFORTABLY NUMB PINK FLOYD 6:14 38 IMMIGRANT SONG LED ZEPPELIN 2:20 39 THE -
Mountain Shepherd
Newsletter of the The Salem United Methodist Church — Wolfsville MMoouunnttaaiinn SShheepphheerrdd Volume 30 March 2012 Number 3 Worship, Fellowship, & Prayer Opportunities at Salem during Lent THEME FOR LENT: “A Journey to Hope” Salem United Methodist Church—Wolfsville IN DIFFICULT INSIDE TIMES WHAT DO YOU GRAB ONTO? Journey to hope Skating Party photos on pages 10 & 11. DISCOVER the HOPE to HANDLE EVERYTHING Missions . 2 Bee-lievers Food Sales . 3 Although the series began Feb 22, you may join us at any time. Bee-lievers Prayer Shawls . 3 Each message can make a difference in our lives right now. Attendance & Offerings . 4 Sticky Buns Sales . 4 JOIN US on THE JOURNEY. Invitations to Church . 4 Follow Christ to the cross this Lenten OPEN Calendar of Events . 5 season. Learn from Pastor Bob’s A NEW Old Sanctuary Photo . 5 teachings on... Who’s Doing What, When? . 6 DOOR It’s Your Day! . 6 Wed Feb 22 Risk (Ash Wednesday) See REAL LIFE SITUATIONS Inspirational Reading . 7 with fresh eyes... Recipe . 7 Sun Feb 26 Choosing our Traveling From Our Pastor . 8 Companions no matter your Women’s Valentine Breakfast 9 Sun Mar 4 Self-Esteem mile marker in life. Snow Tubing/Skating Party 10 Sun Mar 11 Work Easter Flowers Order Form 11 Sun Mar 18 Temptation Commit to attend each week. Heavenly Humor . 12 Sun Mar 25 Money Invite a friend. Encounter Christ. Amazing Bible Facts . 12 Sun Apr 1 Suffering (Palm Sunday) 2 March 2012 The Mountain Shepherd The 22001122 MISSION PROJECTS Mountain Shepherd Monthly Paid 2012 % of Published monthly by Salem United Minimum Jan Goal Goal Methodist Church – Wolfsville. -
WHO Drug Information Vol
WHO Drug Information Vol. 24, No. 4, 2010 World Health Organization WHO Drug Information Contents WHO Prequalification Sitaxentan: worldwide withdrawal 307 Programmes Sibutramine: suspension of sales 307 Sibutramine-containing medicines: WHO Prequalification of Medicines withdrawal 308 Programme: survey of service Testosterone transdermal patch: quality provided to manufacturers 293 withdrawal of extension of WHO initiates pilot prequalification of indication application 308 active pharmaceutical ingredients 297 Aliskiren/valsartan: withdrawal of New on-line database for WHO marketing authorization application 308 prequalified vaccines 298 Mometasone furoate/formoterol fumarate: withdrawal of marketing Safety and Efficacy Issues authorization application 309 EMA and US FDA extend confidentiality H1N1 influenza vaccine: narcolepsy 299 arrangements indefinitely 309 Statins: interstitial lung disease 299 Tocilizumab: risk of fatal anaphylaxis 300 Recent Publications, Pioglitazone: potential bladder cancer 301 Information and Events Angiotensin receptor blockers and US Government to share patents with cancer: safety review 301 Medicines Patent Pool 310 GnRH agonists, diabetes and cardio- Clinical trials and global medicines vascular disease 301 development 310 Gadolinium-based contrast agents: Evaluation of future nanomedicines 311 kidney dysfunction 302 Reporting on opioid inaccessibility 311 Lamotrigine: aseptic meningitis Tinzaparin sodium: renal Impairment in elderly 303 Consultation Documents Tamoxifen: drug interactions involving The -
2018 Medicines in Development for Skin Diseases
2018 Medicines in Development for Skin Diseases Acne Drug Name Sponsor Indication Development Phase ADPS topical Taro Pharmaceuticals USA acne vulgaris Phase II completed Hawthorne, NY www.taro.com AOB101 AOBiome acne vulgaris Phase II (topical ammonia oxidizing bacteria) Cambridge, MA www.aobiome.com ASC-J9 AndroScience acne vulgaris Phase II (androgen receptor degradation Solana Beach, CA www.androscience.com enhancer) BLI1100 Braintree Laboratories acne vulgaris Phase II completed Braintree, MA www.braintreelabs.com BPX-01 BioPharmX acne vulgaris Phase II (minocycline topical) Menlo Park, CA www.biopharmx.com BTX1503 Botanix Pharmaceuticals moderate to severe acne vulgaris Phase II (cannabidiol) Plymouth Meeting, PA www.botanixpharma.com CJM112 Novartis Pharmaceuticals acne vulgaris Phase II (IL-17A protein inhibitor) East Hanover, NJ www.novartis.com clascoterone Cassiopea acne vulgaris Phase III (androgen receptor antagonist) Lainate, Italy www.cassiopea.com Medicines in Development: Skin Diseases ǀ 2018 Update 1 Acne Drug Name Sponsor Indication Development Phase CLS001 Cutanea acne vulgaris Phase II (omiganan) Wayne, PA www.cutanea.com DFD-03 Promius Pharma acne vulgaris Phase III (tazarotene topical) Princeton, NJ www.promiuspharma.com DMT310 Dermata Therapeutics moderate to severe acne vulgaris Phase II (freshwater sponge-derived) San Diego, CA www.dermatarx.com finasteride Elorac severe nodulocystic acne Phase II (cholestenone 5-alpha Vernon Hills, IL www.eloracpharma.com reductase inhibitor) FMX101 Foamix moderate to severe -
A Cycle of C-Changes
A Cycle of C-changes: a working model for the literary epiphany Artur Schouten s1092146 MA thesis June 2014 first reader: Dr. Wim Tigges second reader: Prof. Dr. Peter Liebregts A Cycle of C-changes: a working model for the literary epiphany Schouten 1 Table of Contents: page: 1. Introduction 2 2. Defining epiphany and associated notions 6 3. The literary epiphany - an overview of received knowledge and previous research 10 4. Thesis Statement: A Cycle of C-Changes 25 5. A Portrait of the Artist as a Young Man: entering the world of the artist as he enters into the world 34 6. Vision and revision: the long road to realization in the development of Kerouac’s On the Road 57 7. Conclusion 84 Selected bibliography and works cited 90 A Cycle of C-changes: a working model for the literary epiphany Schouten 2 1. Introduction Change is a keyword in much of the world’s literature, as human beings are hardly ever static and unchanging. Although there are instances in which hardly any change of character, or change of heart, or change of scene occurs in the course of a narrative – Beckett’s Waiting for Godot comes to mind – more often the protagonist’s progress is marked by significant changes. Hence, one of the most commonly discussed aspects when dealing with a work of literature is that of character development. Another key mechanism is that of rising and falling action. This is conventionally associated with drama, but equally applies to prose. Introduced in 1894 by the German critic and dramatist Gustav Freytag (Prince 36), the framework for plot analysis which became known as Freytag’s Pyramid consists of an upright triangular shape depicting on the left-hand side of the triangle the notion of rising action or the increase of tension, the tip of the pyramid representing the climax or culmination of the action, and the right-hand side standing for falling action or the decrease of tension. -
Title "Stand by Your Man/There Ain't No Future In
TITLE "STAND BY YOUR MAN/THERE AIN'T NO FUTURE IN THIS" THREE DECADES OF ROMANCE IN COUNTRY MUSIC by S. DIANE WILLIAMS Presented to the American Culture Faculty at the University of Michigan-Flint in partial fulfillment of the requirements for the Master of Liberal Studies in American Culture Date 98 8AUGUST 15 988AUGUST Firs t Reader Second Reader "STAND BY YOUR MAN/THERE AIN'T NO FUTURE IN THIS" THREE DECADES OF ROMANCE IN COUNTRY MUSIC S. DIANE WILLIAMS AUGUST 15, 19SB TABLE OF CONTENTS Preface Introduction - "You Never Called Me By My Name" Page 1 Chapter 1 — "Would Jesus Wear A Rolen" Page 13 Chapter 2 - "You Ain’t Woman Enough To Take My Man./ Stand By Your Man"; Lorrtta Lynn and Tammy Wynette Page 38 Chapter 3 - "Think About Love/Happy Birthday Dear Heartache"; Dolly Parton and Barbara Mandrell Page 53 Chapter 4 - "Do Me With Love/Love Will Find Its Way To You"; Janie Frickie and Reba McEntire F'aqe 70 Chapter 5 - "Hello, Dari in"; Conpempory Male Vocalists Page 90 Conclusion - "If 017 Hank Could Only See Us Now" Page 117 Appendix A - Comparison Of Billboard Chart F'osi t i ons Appendix B - Country Music Industry Awards Appendix C - Index of Songs Works Consulted PREFACE I grew up just outside of Flint, Michigan, not a place generally considered the huh of country music activity. One of the many misconception about country music is that its audience is strictly southern and rural; my northern urban working class family listened exclusively to country music. As a teenager I was was more interested in Motown than Nashville, but by the time I reached my early thirties I had became a serious country music fan. -
Patent Application Publication ( 10 ) Pub . No . : US 2019 / 0192440 A1
US 20190192440A1 (19 ) United States (12 ) Patent Application Publication ( 10) Pub . No. : US 2019 /0192440 A1 LI (43 ) Pub . Date : Jun . 27 , 2019 ( 54 ) ORAL DRUG DOSAGE FORM COMPRISING Publication Classification DRUG IN THE FORM OF NANOPARTICLES (51 ) Int . CI. A61K 9 / 20 (2006 .01 ) ( 71 ) Applicant: Triastek , Inc. , Nanjing ( CN ) A61K 9 /00 ( 2006 . 01) A61K 31/ 192 ( 2006 .01 ) (72 ) Inventor : Xiaoling LI , Dublin , CA (US ) A61K 9 / 24 ( 2006 .01 ) ( 52 ) U . S . CI. ( 21 ) Appl. No. : 16 /289 ,499 CPC . .. .. A61K 9 /2031 (2013 . 01 ) ; A61K 9 /0065 ( 22 ) Filed : Feb . 28 , 2019 (2013 .01 ) ; A61K 9 / 209 ( 2013 .01 ) ; A61K 9 /2027 ( 2013 .01 ) ; A61K 31/ 192 ( 2013. 01 ) ; Related U . S . Application Data A61K 9 /2072 ( 2013 .01 ) (63 ) Continuation of application No. 16 /028 ,305 , filed on Jul. 5 , 2018 , now Pat . No . 10 , 258 ,575 , which is a (57 ) ABSTRACT continuation of application No . 15 / 173 ,596 , filed on The present disclosure provides a stable solid pharmaceuti Jun . 3 , 2016 . cal dosage form for oral administration . The dosage form (60 ) Provisional application No . 62 /313 ,092 , filed on Mar. includes a substrate that forms at least one compartment and 24 , 2016 , provisional application No . 62 / 296 , 087 , a drug content loaded into the compartment. The dosage filed on Feb . 17 , 2016 , provisional application No . form is so designed that the active pharmaceutical ingredient 62 / 170, 645 , filed on Jun . 3 , 2015 . of the drug content is released in a controlled manner. Patent Application Publication Jun . 27 , 2019 Sheet 1 of 20 US 2019 /0192440 A1 FIG . -
Crth2: Can Residence Time Help ?
CRTh2: Can Residence Time Help ? RSC-SCI Cambridge Medicinal Chemistry Symposium Churchill College, Cambridge 8-11 September 2013 Rick Roberts Almirall Introduction Paul Ehrlich, The Lancet (1913), 182, 445 “A substance will not work unless it is bound” 100 years on: “What a substance does may depend on how long it is bound” 2 In a nutshell …. Introduction “Applications of Binding Kinetics to Drug Discovery” D. Swinney, Pharm. Med. (2008), 22, 23-34 3 Energetic concept of Residence Time kon Standard model [R] + [L] [RL] k unbound off bound Energy ‡ Binding process (kon) is (R·L) determined by the energy barrier Ea E Ligand concentration a Unbinding process (koff) is determines the number of Ed determined by the energy attempts to get over this barrier Ed barrier [R] + [L] G = Ed -Ea [RL] Reaction coordinate Potency (Ki) is determined by the difference in these energies koff Ki = kon 4 K , k , k i on off -1 -1 kon M s Potency (nM) vs kon vs koff Very fast association 108 10 1 0.1 0.01 0.001 107 100 10 1 0.1 0.01 0.001 fast association 106 1000 100 10 1 0.1 0.01 0.001 105 10 M 1000 100 10 1 0.1 0.01 0.001 slow association 104 10 M 1000 100 10 1 0.1 0.01 Very slow association 103 10 M 1000 100 10 1 0.1 “inactive” 102 10 M 1000 100 10 1 10 10-1 10-2 10-3 10-4 10-5 10-6 10-7 s-1 koff Energy A simple binding measurement gives no clue to how fast the association and dissociation are (R·L)‡ Very slow associating compounds that are very slow dissociating (R·L)‡ slow associating compounds that are slow dissociating Are all fast associating compounds -
The Mask We Wear
2622 W. Central - Suite 108, Wichita, KS 67203 316-612-0700 January 2016 Good Grief of Kansas, Inc. Website: www.goodgriefofkansas.org Email: [email protected] The Mask We Wear As we stumble through our I would clench my teeth as a display The mask had not been violently journey of grief, life lessons can of perseverance, and the muscles in ripped off my face but gradually come from the most unexpected my face would strain from this act. removed of my own accord. places. A couple of years ago I went As I continued pretending to be Although the scars remained, it felt to see Andrew Lloyd Webber’s “okay,” my grief was suffocating good to feel the air on my face Phantom of the Opera. I had always underneath. As if trapped under ice again. What I learned from this been intrigued by the story, so experience is that as a society we on a lake, the emotions frantically seeing the play for the first time was still struggle with the subject of captivating. The Phantom’s name looked for way to break through. death. Using the analogy of the was Erik. He was a man with many Pieces of my mask began to chip Phantom of the Opera, imagine the talents, including music, away revealing the pain perspective of Christine as she architecture, magic, and science. underneath. Like the phantom, I stood face to face with the Yet, despite these gifts, people were was afraid of what others might Phantom. To look beneath the mask afraid of him because of his think when the mask was lifted. -
Songbreak Program
presents INTRODUCTION SET 1 Lost is my Quiet, z. 502 (1691) Henry Purcell /unknown Henry Purcell (c.1659-95), often regarded as the dean of English composers, composed this duet, Lost is my Quiet, in 1691 during the height of the middle Baroque period in England. Like the later Baroque composers, Bach and Händel, he was incredibly prolific during his brief 35 years on earth, with a stunning output of masques, oratories, semi-operas, anthems, hymns, cantatas, organ music, incidental music for plays, royal funeral ceremonies and hundreds of songs. His church organist positions, held simultaneously at both the Royal Chapel and Westminster Abbey, made him the most important musician of his era. Purcell is honored, together with Bach and Händel, with a feast day on the liturgical calendar of the Episcopal Church. Lamento (1868) Henri DuParc /Théophile Gautier Frenchman Henri Duparc, who lived from 1848 till 1933, composed this solemn and moving piece in 1868. Plagued by nervousness and anxiety, at age 37 his mental state deteriorated and he completely stopped composing, and eventually destroyed most of his early output. What we have left is a superb body of only seventeen songs giving music to the words of more than a dozen different French poets, of which "Lamento" is one of the finest. Pietá, Signore (1833) François-Joseph Fétis /Anonymous Fétis was a Belgian composer and music critic who lived from 1784-1871. His musical talents manifested at the age of seven and, at nine, he was official church organist at Saint Waltrude. He was a prolific composer from the simple chanson to grand opera. -
Solubility Challenges: Unlocking a Drug’S Potential JULY 2015 Pharmtech.Com
JULY 2015 Volume 39 Number 7 Volume 39 Number 7 Cleaning Stability Tablet Count PLUS: Validation of Biologics in Packaging PHARMACEUTICAL TECHNOLOGY Solubility Challenges: Unlocking a Drug’s Potential JULY 2015 2015 JULY PharmTech.com PEER-REVIEWED Using In-Situ Gelling to Optimize Opthalmic Drug Delivery DRUG DELIVERY OPERATIONAL EXCELLENCE API SYNTHESIS & MANUFACTURING Targeting Drugs to the Colon Data Integrity Continuous API Synthesis magentablackcyanyellow ES639585_PT0715_cv1.pgs 07.07.2015 20:54 ADV magentablackcyanyellow ES639144_PT0715_CV2_FP.pgs 07.06.2015 20:46 ADV INTRODUCING Vion IMS QTof When you’re up against complex samples, sometimes resolution and accurate mass aren’t enough to give you all the information you need. Enter Vion IMS QTof with Collision Cross Section (CCS). A new mass spectrometer that brings ion mobility to the benchtop like never before. Now the analytes you didn’t know were there have nowhere to hide. To learn more, visit waters.com/VION PHARMACEUTICAL n HEALTH SCIENCES n FOOD n ENVIRONMENTAL n CHEMICAL MATERIALS magentablackcyanyellow ES639166_PT0715_003_FP.pgs 07.06.2015 20:46 ADV EDITORIAL SALES Editorial Director Rita Peters [email protected] Publisher Mike Tracey [email protected] Senior Editor Agnes Shanley [email protected] Director of Sales Paul Milazzo [email protected] Managing Editor Susan Haigney [email protected] Mid-West Sales Manager Irene Onesto [email protected] Science Editor Adeline Siew, PhD [email protected] East Coast Sales Manager Joel Kern [email protected] -
Prostanoid Receptors (Version 2019.5) in the IUPHAR/BPS Guide to Pharmacology Database
IUPHAR/BPS Guide to Pharmacology CITE https://doi.org/10.2218/gtopdb/F58/2019.5 Prostanoid receptors (version 2019.5) in the IUPHAR/BPS Guide to Pharmacology Database Richard M. Breyer1, Lucie Clapp2, Robert A. Coleman3, Mark Giembycz4, Akos Heinemann5, Rebecca Hills6, Robert L. Jones7, Shuh Narumiya8, Xavier Norel9, Roy Pettipher10, Yukihiko Sugimoto11, Mohib Uddin12, David F. Woodward13 and Chengcan Yao6 1. Vanderbilt University, USA 2. University College London, UK 3. Pharmagene Laboratories, UK 4. University of Calgary, Canada 5. Otto Loewi Research Center (for Vascular Biology, Immunology and Inflammation), Austria 6. University of Edinburgh, UK 7. University of Strathclyde, UK 8. Kyoto University Faculty of Medicine, Japan 9. Laboratory for Vascular Translational Science, France 10. Atopix Therapeutics Ltd, UK 11. Kumamoto University, Japan 12. AstraZeneca, Sweden 13. Allergan plc, USA Abstract Prostanoid receptors (nomenclature as agreed by the NC-IUPHAR Subcommittee on Prostanoid Receptors [659]) are activated by the endogenous ligands prostaglandins PGD2, PGE1, PGE2 , PGF2α, PGH2, prostacyclin [PGI2] and thromboxane A2. Measurement of the potency of PGI2 and thromboxane A2 is hampered by their instability in physiological salt solution; they are often replaced by cicaprost and U46619, respectively, in receptor characterization studies. Contents This is a citation summary for Prostanoid receptors in the Guide to Pharmacology database (GtoPdb). It exists purely as an adjunct to the database to facilitate the recognition of citations to and from the database by citation analyzers. Readers will almost certainly want to visit the relevant sections of the database which are given here under database links. GtoPdb is an expert-driven guide to pharmacological targets and the substances that act on them.